Compare Workday Inc (WDAY) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Workday Inc vs GeneDx Holdings Corp — how do they compare? Workday Inc trades at $186.7 (market cap $45.26B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Workday Inc is far larger — about 22.4× GeneDx Holdings Corp's market cap, and Workday Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Workday Inc for 38 Days and GeneDx Holdings Corp for 19 Days on average.
| WDAY | WGS | |
|---|---|---|
Market Cap | $45.26B | $2.02B |
Volume | 2,342,190 | 734,640 |
Sector | Technology | Health |
52-Week High | $245.67 | $167.51 |
52-Week Low | $112.55 | $34.51 |
Typical Hold Time | 38 Days | 19 Days |
Enterprise Value | $45.63B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Workday (WDAY) trades at $186.59, up 1.26% on the day, with a neutral technical signal and key support at $185. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.74. Revenue grew to $8.45B in 2025, and net income margin improved to 12.32%. Recent news includes expansion into the UAE and AI product launches, alongside a 2.5% headcount reduction for strategic realignment.
WDAY presents a mixed outlook: analyst consensus is a Buy with a $202.92 price target, signaling upside potential driven by AI integration and revenue growth. However, risks include execution challenges from restructuring, competitive pressures, and a high P/E ratio of 38.25. Investors should weigh strong fundamentals against near-term volatility and macroeconomic headwinds.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Workday Inc
Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.
Read more on WDAY →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
